scholarly article | Q13442814 |
P50 | author | Bobby Nossaman | Q83824922 |
Subramanyam N Murthy | Q89782835 | ||
Philip J. Kadowitz | Q125134318 | ||
Adeleke M Badejo | Q125134349 | ||
Edward A Pankey | Q43160703 | ||
P2093 | author name string | Vaughn E Nossaman | |
Chandrika B Kannadka | |||
Manish Bhartiya | |||
P2860 | cites work | Activation of purified guanylate cyclase by nitric oxide requires heme. Comparison of heme-deficient, heme-reconstituted and heme-containing forms of soluble enzyme from bovine lung | Q72538837 |
Purification and properties of heme-deficient hepatic soluble guanylate cyclase: Effects of heme and other factors on enzyme activation by NO, NO-heme, and protoporphyrin IX | Q72540973 | ||
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential | Q24656131 | ||
NO-independent regulatory site on soluble guanylate cyclase | Q32165040 | ||
Molecular cloning and expression of cDNAs coding for soluble guanylate cyclase from rat lung | Q33258194 | ||
NO-independent, haem-dependent soluble guanylate cyclase stimulators | Q34906036 | ||
Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension | Q34957241 | ||
Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies | Q35044042 | ||
NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle | Q35044464 | ||
Nitric oxide-sensitive guanylyl cyclase: structure and regulation | Q35863606 | ||
Clinical potential of nitric oxide-independent soluble guanylate cyclase activators | Q36269513 | ||
Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation | Q36330594 | ||
The primary structure of the 70 kDa subunit of bovine soluble guanylate cyclase | Q36416369 | ||
Pulmonary vasodilator responses to sodium nitrite are mediated by an allopurinol-sensitive mechanism in the rat. | Q37100160 | ||
Cyclic nucleotides and platelet aggregation effect of aggregating agents on the activity of cyclic nucleotide-metabolizing enzymes | Q39111945 | ||
Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine | Q39140610 | ||
Restoration of the responsiveness of purified guanylate cyclase to nitrosoguanidine, nitric oxide, and related activators by heme and hemeproteins. Evidence for involvement of the paramagnetic nitrosyl-heme complex in enzyme activation | Q39218847 | ||
Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine | Q39269807 | ||
Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation | Q41534405 | ||
Expression of soluble guanylyl cyclase. Catalytic activity requires two enzyme subunits | Q41718282 | ||
YC-1, a novel activator of platelet guanylate cyclase | Q42275468 | ||
Increased responsiveness of the hepatic guanylate cyclase-guanosine 3′,5′-monophosphate system to nitrosoguanidine following partial hepatectomy | Q42445794 | ||
Expression of soluble guanylate cyclase activity requires both enzyme subunits | Q42464263 | ||
NO-independent stimulators of soluble guanylate cyclase | Q43558550 | ||
Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase | Q43950505 | ||
Purification of soluble guanylate cyclase enzyme from human platelets | Q44251326 | ||
Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase | Q44445674 | ||
Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs | Q45091740 | ||
Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus. | Q45193709 | ||
Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. | Q46554951 | ||
Effect of BAY 41-2272 in the pulmonary hypertension induced by heparin-protamine complex in anaesthetized dogs. | Q48632087 | ||
Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid. | Q50909381 | ||
Dissimilarities between methylene blue and cyanide on relaxation and cyclic GMP formation in endothelium-intact intrapulmonary artery caused by nitrogen oxide-containing vasodilators and acetylcholine. | Q50912436 | ||
BAY 41-2272, a Direct Activator of Soluble Guanylate Cyclase, Reduces Right Ventricular Hypertrophy and Prevents Pulmonary Vascular Remodeling during Chronic Hypoxia in Neonatal Rats | Q58351224 | ||
Endothelium-derived relaxant factor inhibits platelet activation | Q69819466 | ||
Activation of soluble guanylate cyclase by NO-hemoproteins involves NO-heme exchange. Comparison of heme-containing and heme-deficient enzyme forms | Q69878955 | ||
Soluble guanylate cyclase from rat lung exists as a heterodimer | Q69881953 | ||
Evidence for the inhibitory role of guanosine 3', 5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators | Q72462196 | ||
P433 | issue | 4 | |
P304 | page(s) | H1153-9 | |
P577 | publication date | 2010-07-16 | |
P1433 | published in | American Journal of Physiology Heart and Circulatory Physiology | Q3193662 |
P1476 | title | Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide | |
P478 | volume | 299 |
Q42502151 | Analysis of responses to glyceryl trinitrate and sodium nitrite in the intact chest rat. |
Q42244904 | Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension |
Q41894813 | Direct sGC activation bypasses NO scavenging reactions of intravascular free oxy-hemoglobin and limits vasoconstriction |
Q37734554 | Inhalative and intravenous stimulation of soluble guanylate cyclase reduces pulmonary vascular resistance and increases cardiac output in experimental septic shock |
Q36532454 | Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling |
Q47977733 | Peroxynitrite has potent pulmonary vasodilator activity in the rat. |
Q34720361 | Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme |
Q53462040 | Relaxant effect of a metal-based drug in human corpora cavernosa and its mechanism of action. |
Q38818645 | Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP? |
Q35010064 | Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease |
Q35075847 | Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension |
Q38000562 | Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications. |
Q38093420 | Stimulators of soluble guanylyl cyclase: future clinical indications |
Q34179857 | Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension. |
Q36923923 | The sGC activator BAY 60-2770 has potent erectile activity in the rat. |
Q54185546 | Vascular dysfunctions in the isolated aorta of double-transgenic hypertensive mice developing aortic aneurysm. |
Search more.